Do you start a statin for cardioprotection in a patient with no lipid indication who is beginning anthracycline chemotherapy?

My answer is that this is a nuanced and shared decision-making discussion.

First, a patient starting new chemo needs a pre-cancer cardiotoxicity risk assessment using the HFA-ICOS risk calculator.

Next, the patient needs optimization of CV risk factors, including lipids- I take a look at prior history...